Umbilical cord blood has several advantages of immediate availability, no risk to donors, a lower risk for acute and chronic GVHD despite major human leukocyte Ag (HLA) disparity, and a lower risk of transmitting infections. As a result of the early successes with pediatric cord blood transplantation (CBT), cord blood from unrelated donors have been increasingly used as an alternative stem cell source for adult patients with hematological malignancies. Recent single-institute and registry-based studies suggest that CBT is a safe, feasible and effective strategy for adult patients without suitable related or unrelated BM donors. In this review, we focus on recent results of myeloablative CBT in adults.
Introduction
Although allo-SCT from a human leukocyte Ag (HLA)-identical related donor offers a potential cure for patients with hematological disorder, a suitably matched related donor is unavailable for approximately two-thirds of patients. As a result of the early successes with pediatric cord blood transplantation (CBT), cord blood from unrelated donors has been increasingly used as an alternative stem cell source for adult patients with hematological malignancies. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Recently several reviews including the clinical results of adult CBT have been published. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] In this review, we focus on recent results of myeloablative CBT in adults.
Cord blood unit selection and factors associated with transplant outcomes after myeloablative CBT in adults Cell dose and HLA matching (by serology or Ag typing for HLA-A and B and by DNA typing for HLA-DRB1) are important factors for a single cord blood unit selection. 33 Gluckman and Rocha 19 reviewed the criteria of cord blood unit choice according to cell dose and HLA matching. Although their recommendations for choosing the best cord blood unit are, in order of preference, HLA 6/6 matched cord blood and 43 Â 10 7 nucleated cells per kg; HLA 5/6 matched cord blood and 44 Â 10 7 nucleated cells per kg; HLA 4/6 matched cord blood and 5410 7 nucleated cells per kg, it is very difficult for adult patients to receive a single cord blood unit of satisfactory nucleated cell dose according to their recommendations. Recently, several studies have suggested promising results of unrelated CBT after myeloablative conditioning for adult patients. However, the factors associated with hematopoietic recovery and GVHD were not fully described.
Hematopoietic recovery
In the early report of Laughlin et al. 3 68 adult patients received a single-unit CBT after myeloablative conditioning. The median weight was 69.2 kg. The median number of nucleated cells before freezing was 2.1 Â 10 7 /kg and the median number of CD34-positive cell dose after thawing was 1.2 Â 10 5 /kg. The estimated probability of neutrophil recovery during the first 42 days was 90% and the median time to neutrophil recovery was 27 days. Although CD34-positive cell dose after thawing and the closeness of HLA matching were not related to the speed of neutrophil recovery, a higher number of nucleated cells in the cord blood before freezing was associated with faster neutrophil recovery. Since CD34 cell dose was not always measured before freezing, the impact of CD34-positive cell dose before freezing on the speed of neutrophil recovery was unclear. However, they found that the number of nucleated cells before freezing correlated with the number of CD34-positive cells present after thawing.
Recently, Arcese et al. 11 reported the updated results of a large series of adult patients with different hematopoietic malignancies transplanted in 63 centers of the Eurocord group. One hundred and seventy-one adult patients received a single-unit CBT after myeloablative conditioning. They analyzed outcomes and risk factors after CBT. The median weight was 62 kg. The median number of nucleated cells before freezing was 2.7 Â 10 7 /kg and the median number of CD34-positive cell dose after thawing was 1.0 Â 10 5 /kg. The cumulative incidence of neutrophil recovery at day 60 was 72% and the median time to neutrophil recovery was 28 days. In multivariate analysis, the number of nucleated cells at collection or freezing, and the use of hematopoietic growth factors within 1 week after transplant were associated with faster neutrophil recovery.
A recent single-institute study at Case Western Reserve University (CWRU) showed the influence of cord blood cell populations on engraftment.
12 Thirty-one patients received a single CBT after myeloablative conditioning. The median weight was 73.4 kg. The median number of nucleated cell infused was 2.17 Â 10 7 /kg and the median number of CD34-positive cell dose after thawing was 1.2 Â 10 5 /kg. The day-42 cumulative incidence of neutrophil recovery was 84% and the median time to neutrophil recovery was 28 days. Univariate analyses demonstrated that there was a strong association between nucleated cell dose, CD3-positive T cells and CD34-positive cell dose and neutrophil engraftment. A higher number of infused CD34 þ HLADR þ CD38 þ progenitor cells were associated with more rapid engraftment.
In our study, 13 , and the use of hematopoietic growth factors after transplant, will be associated with faster neutrophil recovery after a singleunit CBT in adults. The impact of HLA matching on neutrophil recovery remains to be determined.
Graft-versus-host disease
In the report of Laughlin et al., 3 the probability of grade-II to grade-IV and grade-III or grade-IV acute GVHD by 100 days after CBT was 60 and 20%, respectively. There was no statistically significant association between the grade of acute GVHD and the degree of HLA mismatching, mismatching HLA class-II alleles. The probability of chronic GVHD was 38%.
In the report of Eurocord 11 the cumulative incidence of grade-II to grade-IV acute GVHD at 100 days after CBT was 32%. In multivariate analysis, no factor was found to significantly influence the development or severity of acute GVHD. The cumulative incidence of chronic GVHD at 2 years was 36%. In multivariate analysis, no factor showed significant association with the occurrence of chronic GVHD.
Although only 31 patients were analyzed, 12 the study at CWRU showed that high-resolution matching for HLA-DRB1 resulted in decreased risk for grade-III or grade-IV acute GVHD in univariate analysis.
In our study, 13 the cumulative incidence of grade-II to grade-IV and grade-III to grade-IV acute GVHD at day 100 after CBT was 81.5 and 25.1%, respectively. No factor was associated with the incidence of grade-II to grade-IV acute GVHD.
Again, the impact of HLA matching on the incidence and severity of acute and chronic GVHD remains to be determined in adult CBT recipients after myeloablative conditioning.
The IMSUT strategy for choice of graft for hematological malignancies in adult patients without an HLA-matched related donor Patients without a suitable closely HLA-matched family donor were eligible for CBT if a matched unrelated BM donor was unavailable as a first treatment option. If there was insufficient time for an unrelated BM donor search due to disease status or the preliminary search indicated a low likelihood of obtaining a matched unrelated BM donor, we attempted to locate cord blood grafts. On the other hand, if those patients had any type of anti-HLA Ab, we generally attempted to locate BM grafts from unrelated donors because most cord blood grafts were HLA mismatched and the predictable risk of poor engraftment results after CBT. Preferred cord blood units matched four or more of six HLA loci and contained a minimal cell count of 1.5 Â 10 7 nucleated cells per kg before freezing.
Comparisons of cord blood and other stem cell sources
CBT versus unrelated BMT/PBSCT In 2004 two registration-based studies comparing both CBT and BMT from unrelated donors in adult patients with acute leukemia after myeloablative conditioning were published. 34, 35 The study by Laughlin et al. 34 included patients 16-60 years of age who had received either an HLA-matched BMT (n ¼ 367) or a BMT with single HLA mismatch (n ¼ 83) from an unrelated donor, or had received a CBT with one or two HLA mismatches (n ¼ 150). Transplantations were performed between 1996 and 2001 in the United States. Cord blood recipients were younger and more likely to have advanced leukemia than the BM recipients, and they received lower dose of nucleated cells (median, 2.2 Â 10 7 /kg). Hematopoietic recovery was slower in mismatched BMT (20 days) and CBT (27 days) than in matched BMT (18 days). Acute GVHD was more likely to occur after mismatched BMT, and chronic GVHD was more likely to occur after CBT. The rate of transplantrelated mortality (TRM) was lowest among patients received matched BMT. Patients with mismatched BMT and CBT had similar rates of TRM and overall mortality. There were no differences in the rate of recurrence of leukemia among the groups. Leukemia-free survival (LFS) at 3 years was 19% for mismatched BMT, 23% for CBT and 33% for matched BMT.
The study by Rocha et al. 35 included patients at least 15 years of age who had received a single cord blood unit (n ¼ 98) or HLA-matched BM (n ¼ 584). Transplantations were performed between 1998 and 2002 in the Eurocord group. Cord blood recipients were younger, weighed less and were more likely to have advanced leukemia than the BM recipients. All marrow transplants were HLA matched, whereas 94% of cord blood grafts were HLA mismatched. The median number of nucleated cells infused in recipients of cord blood was 2.3 Â 10 7 /kg. Neutrophil recovery was significantly delayed after CBT (26 days) as compared with BMT (19 days). Multivariate analysis showed lower risks of acute GVHD after CBT. The incidence of chronic GVHD, TRM, and relapse rate were not significantly different in the two groups. LFS at 2 years was also similar in the two groups (33% for CBT and 38% for BMT).
In 2004, our group also reported on a comparative analysis of CBT vs BMT from unrelated donors in adults after myeloablative conditioning in our institute. 36 The study included data from 113 patients, 16 7 /kg. Neutrophil recovery was significantly delayed after CBT (22 days) as compared with BMT (18 days). However, the overall results for CBT recipients were better than those for for BMT recipients in terms of GVHD, TRM and disease-free survival (DFS). DFS at 2 years was 74% for CBT and 44% for BMT. In our assessments, the availability of grafts containing sufficient cell number, the shorter time from donor search to transplantation, the low requirements of steroid therapy for GVHD, the conditioning regimen including TBI, avoidance of antithymocyte globlin, the GVHD prophylaxis with standard cyclosporine (CyA) and MTX used in our institution, and Japanese genetic issues regarding low alloreactivity, might have contributed to our favorable results of CBT in adults.
Recently Eapen et al. 37 reported a comparative analysis of CBT from unrelated donor with BM or peripheral blood stem-cell transplants (PBSCT) from unrelated donors in adults after myeloablative conditioning. The study included data from 1240 adults aged 16 years or older with acute leukemia (AML, n ¼ 707; acute lymphoblastic leukemia (ALL), n ¼ 533) who received T-cell-replete BMT (n ¼ 354) or T-cell-replete PBSCT (n ¼ 728) from unrelated donors or unrelated CBT (n ¼ 148). Transplantations were performed between 2002 and 2006. Neutrophil recovery was poorest in recipients of CBT. TRM was less in recipients of 8/8 HLA-matched PB (27%) and BM (26%) as compared with those transplanted with 7/8 HLA-matched PB (42%) or 7/8 HLA-matched BM (37%) or CB (41%). LFS was highest in recipients of 8/8 HLA-matched PB (43%) and BM (46%), with no significant differences in LFS in recipients of CB (33%) and 7/8 HLA-matched PB (33%) and BM (34%).
CBT versus related BMT/PBSCT
Recently our group reported a comparative analysis of CBT from unrelated donor with BMT or PBSCT from related donors in adults after myeloablative conditioning. 38 The study included data from 171 patients, 16 years or older, who received BMT (n ¼ 55) or PBSCT (n ¼ 16) from related donors or unrelated CBT (n ¼ 100). Transplantations were performed between 1997 and 2005. The median number of nucleated cells before freezing in recipients of cord blood was 2.43 Â 10 7 /kg. Neutrophil recovery was significantly delayed after CBT (22 days) as compared with that in BMT/PBSCT (17 days). However, overall engraftment rates were almost the same for both grafts. The cumulative incidence of grade-III to grade-IV acute and extensive-type chronic GVHD among CBT recipients was significantly lower than those among BMT/PBSCT recipients. Multivariate analysis demonstrated no apparent differences in TRM, relapse and DFS between both groups. DFS at 3 years was 70% for CBT and 60% for BMT/PBSCT. These data suggest that unrelated cord blood could be safe and effective a stem cell source as related BM or mobilized peripheral blood when it is used as a primary unrelated stem cell source in the experienced institutes.
CBT versus haploidentical PBSCT Rocha et al. 20 analyzed data from adult patients with ALL or AML who received either CBT or haploidentical transplantation performed in EBMT centers from 1998 to 2002. One hundred forty-four patients had ALL (haploidentical, n ¼ 75; CBT, n ¼ 73) and 220 had de novo AML (haploidentical, n ¼ 154; CBT, n ¼ 66). CBT patients were younger than haploidentical recipients. The frequency of patients with an advanced phase of disease at transplantation was similar. CBT recipients had delayed neutrophil recovery and higher incidence of grade-II to grade-IV acute GVHD. In the AML group, relapse incidence, TRM and LFS (30% at 2 years in CBT and 24% in haploidentical transplant) were not statistically different after CBT or haploidentical; however, in the ALL group LFS was superior after CBT (36% at 2 years) as compared with haploidentical transplantation (13% at 2 years) because of a decreased incidence of relapse after CBT.
Disease-specific outcomes
Acute myeloid leukemia Reports of disease-specific outcomes for adult patients with AML after CBT are still limited. 7 In the report of Rocha et al. 35 98 adult patients received CBT. Among them 45 had AML and 2-year leukemia-free survival was 32%. Since this report was registry-based retrospective studies comparing the results of unrelated CBT and unrelated BMT in adults, the details of outcomes of AML were not described. Recently Brunstein et al. 25 reported the results from 33 adult patients with AML who received CBT after myeloablative conditioning at the University of Minnesota. Overall survival is 58% and LFS is 54%. Recently, we updated the results of unrelated CBT after myeloablative conditioning for 77 adult patients with AML. 13 Between August 1998 and February 2008, 77 adult patients with AML were treated with unrelated CBT. All patients received four fractionated 12-Gy TBI and chemotherapy as myeloablative conditioning. The median age was 45 years, the median weight was 55 kg, the median number of nucleated cells was 2.44 Â 10 7 /kg and the median number of CD34-positive cells was 1.00 Â 10 5 /kg. All patients received a single and HLA-mismatched cord blood unit. The cumulative incidence of neutrophil recovery at day 50 and plt recovery at day 200 was 94.8 and 91.7%, respectively. As previously described, a higher CD34-positive cell dose was associated with faster hematopoietic recovery. The cumulative incidence of grade-III to grade-IV acute GVHD and extensive-type chronic GVHD was 25.1 and 28.6%, respectively. With a median follow-up of 78 months, the probability of EFS at 5 years was 62.8%. The 5-year cumulative incidence of TRM and relapse was 9.7 and 25.8%, respectively. In multivariate analyses, the risk factors identified for EFS were disease status and cytogenetics.
Acute lymphoblastic leukemia Reports of disease-specific outcomes for adult patients with ALL after cord CBT are also limited. 8 In the report of Rocha et al. 35 98 adult patients received CBT. Among them 53 had ALL and the 2-year probability of LFS was 34%. Recently, Kumar et al. 39 reported the results of 19 adult patients with ALL who received a single-or double-unit CBT after myeloablative conditioning at the University of Minnesota. Overall survival was 66% and LFS was 61%. Recently, we updated the results of unrelated CBT after myeloablative conditioning for 27 adult patients with ALL. 40 Between October 2000 and November 2007, 27 adult patients with ALL were treated with unrelated CBT. All patients received four fractionated 12-Gy TBI and chemotherapy as myeloablative conditioning. The median age was 36 years, the median weight was 57 kg and the median number of nucleated cells was 2.47 Â 10 7 /kg. All patients received a single and HLAmismatched cord blood unit. The cumulative incidence of neutrophil recovery at day 30 and plt recovery at day 200 was 92.6 and 92.3%, respectively. With a median follow-up of 47 months, the probability of EFS at 5 years was 57.2%. The 5-year cumulative incidence of TRM and relapse was 3.7 and 27.4%, respectively.
Chronic myeloid leukemia
There are very limited reports of adult chronic myeloid leukemia (CML) patients who received CBT after myeloablative conditioning. The Eurocord group reported the results from 171 adult patients with different hematopoietic malignancies received CBT after myeloablative conditioning. 11 Of the 171 patients, 32 patients had CML and six patients in blast crisis (BC). DFS at 2 years was 19%. Brunstein et al. 26 reported the data of 20 CML patients received CBT at the University of Minnesota. Fourteen patients were in accelerated phase or second chronic phase and six in first chronic phase. DFS at 2 years was 50%. Recently, Nagamura-Inoue et al. 41 reported the data from 86 CML patients who received CBT in Japan. Of the 86 patients 77 patients were adult and 66 received myeloablative conditioning. LFS at 2 years was 38%. LFS at 2 years was 52% in chronic phase, 38% in accelerated phase and 22% in blast crisis.
Myelodysplastic syndrome
Again, reports of disease-specific outcomes for adult patients with myelodysplastic syndrome after CBT are still limited. 6 The Eurocord group reported the results from 16 adult patients with myelodysplastic syndrome who received CBT after myeloablative conditioning.
11 DFS at 2 years was 25%. We reported the results of CBT after myeloablative conditioning for 22 adult patients with myelodysplastic syndrome. 42 All patients received four fractionated 12-Gy TBI and chemotherapy as myeloablative conditioning. The median age was 40 years, the median weight was 54.5 kg and the median number of cryopreserved nucleated cells was 2.43 Â 10 7 /kg. Twenty-one patients had myeloid reconstitution and the median time to neutrophil recovery was 22.5 days. DFS at 4 years was 76%.
Lymphoma and chronic lymphocytic leukemia
The Eurocord group reported the results from 104 adult patients with lymphoid malignancies who received CBT. 43 Diagnoses were non-Hodgkin's lymphoma (n ¼ 61), Hodgkin's lymphoma (n ¼ 29), and chronic lymphocytic leukemia (n ¼ 14). Of the 104 patients, 36 received CBT after myeloablative conditioning and 26 received double CBT. The cumulative incidence of neutrophil engraftment by day 60, the cumulative incidence of TRM at 1 year, the cumulative incidence of relapse or progression at 1 year was 84, 28 and 31%, respectively. The probability of progression-free survival at 2 years was 36%. Chemosensitive disease, use of low-dose TBI and higher cell dose were factors associated with significantly better outcome.
New strategies to enhance engraftment and reduce TRM
To overcome the limited number of cells available in a single unit, several strategies have been reported for adults. [44] [45] [46] [47] [48] Double CBT Barker et al. 44 reported the early results of double CBT in adults with hematological malignancy after myeloablative conditioning at the University of Minnesota. Twenty-three patients received two partially HLA-matched cord blood units after myeloablative conditioning. All evaluable patients (n ¼ 21) engrafted at a median of 23 days. DFS was 57% at 1 year, with 72% of patients alive if they received transplants while in remission. Updated data of double CBT after myeloablative conditioning at the University of Minnesota has been reported. 32 Eighty-three patients received double CBT after myeloablative conditioning. DFS was 54% at 3 years. Recently they reported an analysis of acute GVHD in 265 patients transplanted with cord blood graft composed of one (n ¼ 80) or two (n ¼ 185) units. 45 The incidence of grade-II to grade-IV acute GVHD was higher among double CBT recipients. However, TRM at 1 year was significantly lower after double CBT.
Although, double CBT has been recognized one of the most attractive strategies to enhance engraftment, single-vs double-unit myeloablative CBT randomized trial, which is now underway in the US in children, should be investigated to answer the question of the utility of double CBT in adults.
Direct intra-bone transplant of cord blood cells To reduce losses of cord blood that may get trapped in other organs after i.v. injection, a new administration route for cord blood cells has been explored. Recently, Frassoni et al. 46 reported the preliminary data of direct intra-bone CBT. Thirty-two adult patients with acute leukemia received intra-bone CBT. Of them two patients received a reduced-intensity conditioning. No complications occurred during or after intra-bone infusion of cord blood cells. Four patients had early death within 12 days after CBT. Median time to recovery of neutrophils in 28 patients was 23 days and median time to recovery of plts in 27 patients was 36 days. No patients developed grade-III or grade-IV acute GVHD.
These findings will need confirmation in larger studies with longer follow-up.
CBT supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor To reduce the period of posttransplant neutropenia and related early morbidity and mortality of CBT, Fernandez et al. 47, 48 have developed a strategy consisting of a single unit of cord blood following myeloablative conditioning, supported by the co-infusion of a relatively low number of T-cell-depleted, mobilized hematopoietic stem cells from a third party donor. They reported the updated results from 55 adult patients with high-risk hematological malignancies transplanted using this strategy. 49 Median time to recovery of neutrophils was 10 days and median time to cord bloodderived neutrophil recovery was 21 days. The cumulative incidence of grade-III or grade-IV acute GVHD was 11%. Overall survival and DFS at 5 years were 56 and 47%, respectively. This strategy also will need confirmation in larger studies with longer follow-up.
Ex vivo expansion
For details on ex vivo expansion see review by Shpall et al.
Reduced-intensity conditioning
To reduce TRM after CBT in adults, reduced-intensity or non-myeloablative conditioning regimens have been developed 50, 51 (for details see review by Ballen et al.).
Conclusion
Cord blood has emerged as an acceptable alternative source of hematopoietic stem cell for transplantation in adult patients with hematological malignancies. Several singleinstitute reports have demonstrated encouraging outcomes of a single-unit CBT after myeloablative conditioning in adults. To enhance engraftment and reduce early TRM, several new strategies have been developed.
